Survey: 63% of ALK Lung Cancer Patients Pay Over HK$10,000 Monthly Out-of-Pocket
AM730 · 2 SOURCESabout 5 hours ago2 MIN
Summary
The Cancer Information Network Charity Fund released findings from its 2026 online survey on non-small cell lung cancer patients, revealing that financial burden significantly impacts treatment decisions for ALK-positive patients in Hong Kong. The survey of 104 patients, including 30 with ALK mutations, found that 63% of ALK-positive patients face monthly out-of-pocket medical costs exceeding HK$10,000, while 42% of all respondents live in households with monthly incomes below HK$20,000. Facing such economic pressure, half of all patients have traveled to mainland China to purchase less expensive medications, though nearly 90% indicated they would remain in Hong Kong for treatment if government subsidies were available.
Key Points
- The Cancer Information Network Charity Fund conducted an online survey in July to August 2026, collecting responses from 104 non-small cell lung cancer patients, including 30 ALK-positive patients for subgroup analysis .
- The survey found that 63% of ALK-positive lung cancer patients incur monthly out-of-pocket medical expenses exceeding HK$10,000, covering targeted medications, private CT scans, and PET-CT imaging .
- Among all surveyed patients, 42% live in households with monthly incomes below HK$20,000, creating substantial financial barriers to continued treatment .
- About 50% of patients have traveled north to mainland China to purchase cheaper medications, with over 80% citing cost as the primary motivation for cross-border healthcare-seeking .
- If the Hong Kong government provides subsidies for lung cancer medications, nearly 90% of ALK-positive patients would stay in Hong Kong for treatment or reduce their need to travel north .
Why It Matters
ALK-positive lung cancer represents approximately 5% of all lung cancer cases and primarily affects non-smokers, making it a distinct disease entity requiring targeted therapy . With the third-generation ALK inhibitor demonstrating a median progression-free survival exceeding 84 months, this cancer has increasingly become manageable as a chronic condition . However, the high cost of medications without government support forces patients to choose between financial hardship and treatment continuity, potentially compromising clinical outcomes for a treatable disease .
ALK-positive lung cancer represents approximately 5% of all lung cancer cases and primarily affects non-smokers, making it a distinct disease entity requiring targeted therapy . With the third-generation ALK inhibitor demonstrating a median progression-free survival exceeding 84 months, this cancer has increasingly become manageable as a chronic condition . However, the high cost of medications without government support forces patients to choose between financial hardship and treatment continuity, potentially compromising clinical outcomes for a treatable disease .